Biogen Inc. (SIX: BIIB.SW) AI-Powered Stock Analysis
See how Biogen Inc. scores across key metrics like financial growth, valuation, and market position on the SIX, using AI-driven evaluation.
BIIB.SW●SIX
HealthcareDrug Manufacturers - General
CHF141.03
CHF6.43(4.36%)
Swiss Market opens in 6h 12m
Biogen Inc. (SIX: BIIB.SW) AI-Powered Stock Analysis
See how Biogen Inc. scores across key metrics like financial growth, valuation, and market position on the SIX, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerBiogen Inc. (SIX: BIIB.SW) Stock Overall Grade
Biogen Inc.'s grade for its SIX listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Biogen Inc.'s overall SIX stock rating.
Forecast
A+Score
92/100Financial Growth
BScore
60/100Fundamental Growth
C+Score
50/100Key Ratios
B+Score
77/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Biogen Inc. (SIX: BIIB.SW) AI-Powered Stock Analysis
On the SIX, BIIB.SW demonstrates Good performance with an overall Forecast Score of 92/100 (A+), reflecting high confidence in its potential. Financial Growth (60/100, B) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (77/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the SIX-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(SIX: BIIB.SW) Component Analysis Explained
Understand the key factors behind each Biogen Inc. (SIX: BIIB.SW) stock grade, including financials, comparisons, and forecasts.